Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IL-2 pre-treated CD19 CAR-T cells
- Development stage
- Unknown
- Lead developer
- Jiang Jingting
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
IL-2 pre-treated CD19 CAR-T cells are an investigational cell therapy developed by Jiang Jingting for the treatment of refractory or chemotherapy-resistant CD19+ B-cell lymphoma. The therapy involves T cells engineered with a chimeric antigen receptor (CAR) targeting CD19, featuring a CD28 costimulatory domain and a TCRζ signaling domain. A distinguishing feature of this specific product is the ex vivo stimulation and expansion of the CAR-T cells using Interleukin-2 (IL-2) prior to patient infusion. This approach is being clinically evaluated to determine if IL-2 pre-treatment enhances the safety, efficacy, and persistence of the CAR-T cells compared to other cytokine stimulation protocols, such as those using IL-7 and IL-15.
- Other names
- IL-2 stimulated CD19 CAR-T cellsIL2 stimulated CD19 CAR-T cellsIL 2 stimulated CD19 CAR-T cellsIL-2 pre-treated CD19 cellsIL2 pre-treated CD19 cellsIL 2 pre-treated CD19 cellsCD19-targeted TCRζ chimeric antigen receptor-T cellsAnti-CD19:TCRζ Chimeric Antigen Receptor-T Cells
02
Targets
IL2RB (IL-2 receptor beta chain)CD19 (B lymphocyte antigen CD19)
Beyond the preview
Go deeper on IL-2 pre-treated CD19 CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IL-2 pre-treated CD19 CAR-T cells.